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Background:  PCSK9 antibodies under development require dosing every (Q) 2 weeks (W) or large monthly doses to maintain sustained 
LDL-C reductions. LY3015014 (LY) is a humanized monoclonal antibody with an inherently longer duration of action. This phase 2 study 
assessed the LDL-C lowering effect of LY given every 4 or 8 weeks to patients with primary hypercholesterolemia, when added to standard 
of care lipid lowering therapy, including statins. 
methods:  Patients were randomized to receive subcutaneous injections of LY 20 mg, 120 mg or 300 mg Q4W; 100 mg or 300 mg 
Q8W (alternating with placebo Q4W); or placebo Q4W. The primary endpoint was percentage change from baseline in LDL-C (by beta 
quantification) at week 16. Safety and tolerability were also assessed. 
results:  527 patients were randomized and 519 received study drug. LY demonstrated dose related decreases in LDL-C, with up to 51% 
reduction maintained at the end of the dosing interval (see table). There were no treatment related serious adverse events. The most 
common adverse event terms (≥10% of any treatment group) were nasopharyngitis, injection site pain, headache, injection site erythema 
and back pain. No liver or muscle safety issues emerged. 
Conclusion:  The PCSK9 antibody, LY, dosed every 4 or 8 weeks, resulted in robust and durable reductions in atherogenic (apo)
lipoproteins, including LDL-C, non-HDL-C, ApoB and Lp(a). No clinically relevant safety issues emerged with the administration of LY.
